Antimicrobial resistance of Mycobacterium avium during the COVID-19 pandemic DOI Creative Commons
I. А. Vаsilyevа,

A.E. Panova,

Valentina Tinkova

et al.

Clinical Microbiology and Antimicrobial Chemotherapy, Journal Year: 2024, Volume and Issue: 26(4), P. 462 - 469

Published: Jan. 1, 2024

Objective. Conduct a comparative assessment of the frequency and spectrum antimicrobial resistance Mycobacterium avium isolated from patients phthisiopulmonology clinic in pre-Covid period (2018–2019) during COVID-19 pandemic (2020–2023). Materials Methods. The sensitivity M. isolates was determined to 8 drugs: amikacin, clarithromycin, linezolid, moxifloxacin, ciprofloxacin, doxycycline, rifabutin, rifampicin. Drug susceptibility testing performed using serial broth microdilution method according published CLSI guidelines, M24S, 2023. Interpretation results, classifying into one three categories: sensitive, intermediate, resistant, carried out based on comparison values minimum inhibitory concentrations (MIC) drugs with breakpoint these parameters complex breakpoints were used for moxifloxacin. For rifampicin, other slow-growing non-tuberculous mycobacteria (NTM) (M. kansasii marinum) rules section 2023 “Non-species related breakpoints”. Results. A analysis (2018– 2019) (2020–2023) showed an increase proportion resistant clarithromycin (from 1.1% 20.1%, p < 0.0001), moxifloxacin 11.0% 29.2%, = 0.0007) intermediate drug 5.6% 17.6%, 0.0080) pandemic. opposite trend is noteworthy – sensitive amikacin 55.5% 79.6%, 0.0001) decrease 36% 4.4%, 0.0001). In addition, there ciprofloxacin 18.8% 9.7%, 0.0288) linezolid 27.7% 17.2%, 0.039). Conclusions. data obtained this work occurrence main reserve antimicrobials requires search new that are effective against infection caused by avium. It necessary expand MIC existing develop reasonable criterion establishing clinical categories resistance, as well revise recommendations group tested NTM determine treatment regimens.

Language: Английский

Bacterial Infections, Trends, and Resistance Patterns in the Time of the COVID-19 Pandemic in Romania—A Systematic Review DOI Creative Commons
Dan Dumitru Vulcănescu, Iulia Cristina Bagiu,

Cecilia Roberta Avram

et al.

Antibiotics, Journal Year: 2024, Volume and Issue: 13(12), P. 1219 - 1219

Published: Dec. 14, 2024

Background: The COVID-19 pandemic has intensified concerns over bacterial infections and antimicrobial resistance, particularly in Romania. This systematic review explores infection patterns resistance during the to address critical gaps knowledge. Methods: A review, following PRISMA guidelines, was conducted using databases such as PubMed Scopus, focusing on studies of from 2020 2022. Articles Romanian patients were analyzed for demographic data, trends, profiles. Results: total 87 included, detailing 20,000 cases infections. found that Gram-negative bacteria, Escherichia coli Klebsiella pneumoniae, most frequently identified pathogens, alongside Gram-positive Staphylococcus aureus Enterococcus spp. Multidrug (MDR) noted 24% reported strains, with common carbapenems cephalosporins. Conclusions: amplified complexity managing infections, critically ill patients. rise MDR bacteria underscores need stringent stewardship control measures. Continuous monitoring trends profiles will be essential improve treatment strategies post-pandemic healthcare settings.

Language: Английский

Citations

2
Multiple impacts of the COVID-19 pandemic and antimicrobial stewardship on antimicrobial resistance in nosocomial infections: an interrupted time series analysis DOI Creative Commons
Weibin Li, Xinyi Yang, Chaojie Liu

et al.

Frontiers in Public Health, Journal Year: 2024, Volume and Issue: 12

Published: July 17, 2024

Objectives The emergency response to the COVID-19 pandemic may disrupt hospital management activities of antimicrobial resistance (AMR). This study aimed determine changing AMR trend over period in China when stringent measures were implemented. Methods retrospective was conducted a designated for patients Guangzhou, from April 2018 September 2021. prevalence 13 antimicrobial-resistant bacteria compared before and after responses through Chi-square tests. Interrupted time series (ITS) models on weekly established trend. Controlled ITS performed compare differences between subgroups. Results A total 10,134 isolates 1,265 days collected. And strains presented 38.6% testing isolates. decreased by 0.29 percentage point (95% CI [0.05–0.80]) stewardship (AMS) policy, despite an increase penicillin-resistant Streptococcus pneumoniae (from 0/43 15/43, p &lt; 0.001), carbapenem-resistant Escherichia coli 20/1254 41/1184, = 0.005), Klebsiella 93/889 114/828, 0.042). did not vary gender (male vs. female), age (&lt;65 ≥65 years), service setting (outpatient inpatient), care unit (ICU non-ICU), primary site infection (Lung others), Gram type (positive negative). Conclusion lead overall AMR; however, it appears that strategy prudent use antimicrobials likely contributed sizable long-term drop. frequency several multidrug-resistant continues epidemic. It is crucial continue monitor cases have surged relaxation restriction measures.

Language: Английский

Citations

1
Global prevalence of human intestinal carriage of ESBL-producing E. coli during and after the COVID-19 pandemic DOI Creative Commons
Rita W. Y. Ng,

Liuyue Yang,

Sai Hung Lau

et al.

JAC-Antimicrobial Resistance, Journal Year: 2024, Volume and Issue: 7(1)

Published: Dec. 26, 2024

Abstract Background There is a pressing need for global surveillance of ESBL-producing Escherichia coli due to its health impacts, travel and increased antibiotic use during the COVID-19 pandemic. This systematic review meta-analysis aimed summarize evidence investigating prevalence ESBL E. coli. Methods Four databases, including Embase, MEDLINE, PubMed Web Science, were searched quantitative studies that reported data faecal carriage published between 23 April 2021 22 2024. Meta-analysis was performed using inverse variance heterogeneity model. Results Of 25 (13 901 unique participants) included final analysis, overall pooled 25.4% (95% CI, 19.7%–31.2%). The prevalences in healthy individuals community settings inpatients healthcare 23.4% 14.7%–32.2%) 27.7% 18.8%–36.7%), respectively. Nearly one-third (32%) from Western Pacific Region. significant between-group difference with different WHO regions contact. Conclusions remains high there regions, highest being Asian regions. Standardized antimicrobial resistance stewardship especially these are needed enhance control this emergency.

Language: Английский

Citations

1
Multidrug-resistant Organism and Antibiotic Sensitivity Patterns, before, during, and after the Coronavirus Disease 2019 Pandemic in the Dr. M. Djamil Central General Hospital, Padang, Indonesia DOI Creative Commons
Fadrian Fadrian, Linosefa Linosefa,

Armen Ahmad

et al.

Biomedical and Biotechnology Research Journal (BBRJ), Journal Year: 2024, Volume and Issue: 8(3), P. 279 - 290

Published: July 1, 2024

Abstract Background: The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted the prevalence and antibiotic sensitivity patterns of multidrug-resistant organisms (MDROs). This study aimed to investigate MDRO incidence trends before, during, after COVID-19 at Dr. M. Djamil Central General Hospital in Padang, Indonesia. Methods: A total 5539 clinical samples were collected analyzed using VITEK2 system identify types. periods defined as before (prepandemic), pandemic. Results: MDROs increased during pandemic, with 1.64 1.42 times higher rates compared prepandemic period, respectively. Specific types that showed included Escherichia coli -producing extended-spectrum β-lactamases (Eco-ESBL), carbapenem-resistant Klebsiella pneumoniae (CRKP), E. (CREC), Pseudomonas aeruginosa (CRPA), Acinetobacter baumannii (CRAB), methicillin-resistant Staphylococcus aureus (MRSA). Antibiotic decreased for K. ESBL s, CRKP, CRAB, well CREC CRPA In contrast, Eco-ESBL MRSA Conclusion: contributed effectiveness against these pathogens setting. These findings highlight need comprehensive infection control measures antimicrobial stewardship programs mitigate impact on epidemiology.

Language: Английский

Citations

0
Early Antiviral Use and Supplemental Oxygen Decrease the Risk of Secondary Bacterial Infections: A Multicentre Nested Case-Control Study DOI
Yixing Zhu,

Haiming Hu,

Xin Guo

et al.

Journal of Hospital Infection, Journal Year: 2024, Volume and Issue: 156, P. 87 - 95

Published: Dec. 17, 2024

Language: Английский

Citations

0
Guanethidine Enhances the Antibacterial Activity of Rifampicin Against Multidrug-Resistant Bacteria DOI Creative Commons
Xiaoou Zhao, Zhenxue Zhang, Leying Liu

et al.

Microorganisms, Journal Year: 2024, Volume and Issue: 12(11), P. 2207 - 2207

Published: Oct. 31, 2024

The escalating global threat of antibiotic resistance necessitates innovative strategies, such as the combination antibiotics with adjuvants. Monotherapy rifampicin is more likely to induce in pathogens compared other antibiotics. Herein, we found that antihypertensive drug guanethidine enhanced activity against certain clinically resistant Gram-negative bacteria, resulting a reduction up 128-fold minimum inhibitory concentration. In infected animal models, this has achieved treatment benefits, including increased survival and decreased bacterial burden. antimicrobial mechanism synergy involves disruption outer membrane leading dissipation proton motive force. This results an increase reactive oxygen species ATP synthesis, severely disturbing energy metabolism ultimately increasing mortality. summary, potential become novel adjuvant for rifampicin, offering new option clinical infections.

Language: Английский

Citations

0
Antimicrobial resistance of Mycobacterium avium during the COVID-19 pandemic DOI Creative Commons
I. А. Vаsilyevа,

A.E. Panova,

Valentina Tinkova

et al.

Clinical Microbiology and Antimicrobial Chemotherapy, Journal Year: 2024, Volume and Issue: 26(4), P. 462 - 469

Published: Jan. 1, 2024

Objective. Conduct a comparative assessment of the frequency and spectrum antimicrobial resistance Mycobacterium avium isolated from patients phthisiopulmonology clinic in pre-Covid period (2018–2019) during COVID-19 pandemic (2020–2023). Materials Methods. The sensitivity M. isolates was determined to 8 drugs: amikacin, clarithromycin, linezolid, moxifloxacin, ciprofloxacin, doxycycline, rifabutin, rifampicin. Drug susceptibility testing performed using serial broth microdilution method according published CLSI guidelines, M24S, 2023. Interpretation results, classifying into one three categories: sensitive, intermediate, resistant, carried out based on comparison values minimum inhibitory concentrations (MIC) drugs with breakpoint these parameters complex breakpoints were used for moxifloxacin. For rifampicin, other slow-growing non-tuberculous mycobacteria (NTM) (M. kansasii marinum) rules section 2023 “Non-species related breakpoints”. Results. A analysis (2018– 2019) (2020–2023) showed an increase proportion resistant clarithromycin (from 1.1% 20.1%, p < 0.0001), moxifloxacin 11.0% 29.2%, = 0.0007) intermediate drug 5.6% 17.6%, 0.0080) pandemic. opposite trend is noteworthy – sensitive amikacin 55.5% 79.6%, 0.0001) decrease 36% 4.4%, 0.0001). In addition, there ciprofloxacin 18.8% 9.7%, 0.0288) linezolid 27.7% 17.2%, 0.039). Conclusions. data obtained this work occurrence main reserve antimicrobials requires search new that are effective against infection caused by avium. It necessary expand MIC existing develop reasonable criterion establishing clinical categories resistance, as well revise recommendations group tested NTM determine treatment regimens.

Language: Английский

Citations

0